Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06266546 · ClinicalTrials.gov registry record · Phase 3
Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy
A Phase 3 study of Hemorrhage Lung and Endobronchial Mass, sponsored by Youssef Yammine.
- Active
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06266546 is a Phase 3 study of Hemorrhage Lung and Endobronchial Mass that is active but no longer recruiting, run by Youssef Yammine. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06266546, a Phase 3 study of Hemorrhage Lung and Endobronchial Mass, is active but no longer recruiting, sponsored by Youssef Yammine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Transbronchial cryobiopsies are common procedures used to obtain tissue samples from airways for diagnostic purposes. While these procedures are safe, there is a risk of bleeding from the biopsy site. We are conducting a research study to assess the safety and effectiveness of using tranexamic acid prior to undergoing a transbronchial cryobiopsy.
Conditions Studied
Interventions
- DRUG Tranexamic acid
Study Locations (1)
Kansas
- Ascension Via Christi - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06266546
The ClinicalTrials.gov registry entry for NCT06266546 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Youssef Yammine, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hemorrhage Lung appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid is the first listed.
NCT06266546 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06266546 about?
NCT06266546 is a clinical study titled "Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy". Transbronchial cryobiopsies are common procedures used to obtain tissue samples from airways for diagnostic purposes. While these procedures are safe, there is a risk of bleeding from the biopsy site. We are conducting a research study to assess the safety and effectiveness of using tranexamic acid ...
What is the current status of trial NCT06266546?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2024-03-01. Estimated completion is 2025-03-01.
What conditions does trial NCT06266546 study?
This clinical trial studies the following conditions: Hemorrhage Lung, Endobronchial Mass.
What interventions are being tested in trial NCT06266546?
The interventions under investigation include: Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT06266546?
This trial is sponsored by Youssef Yammine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06266546 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.